DNA TESTING CENTERS CORP (DNAT) financial statements (2020 and earlier)

Company profile

Business Address 2378 PARKHAVEN
OAKVILLE, ON L6H 0E7
State of Incorp. FL
Fiscal Year End December 31
SIC 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2018
Q4
12/31/2017
Q4
9/30/2017
Q3
6/30/2017
Q2
3/31/2017
Q1
12/31/2016
Q4
9/30/2016
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4783828346
Cash and cash equivalents4783828346
Receivables0 123  
Prepaid expense0      
Other undisclosed current assets     22
Total current assets:48838310668
Noncurrent Assets
Property, plant and equipment3344444
Total noncurrent assets:3344444
TOTAL ASSETS:5087871391013
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:4033212326  
Other undisclosed accounts payable and accrued liabilities4033212326  
Due to related parties15012911910694  
Other undisclosed current liabilities      62
Total current liabilities:189161140128121 62
Noncurrent Liabilities
Other undisclosed liabilities     120 
Total liabilities:18916114012812112062
Stockholders' equity
Stockholders' equity attributable to parent, including:(139)(75)(53)(115)(111)(110)(50)
Common stock2222222
Common stock, value, subscriptions100100100    
Additional paid in capital206221221221221221221
Accumulated other comprehensive loss(13)(23)(22)(12)(10)(10) 
Accumulated deficit(435)(376)(355)(326)(324)(323)(261)
Other undisclosed stockholders' equity attributable to parent      (12)
Total stockholders' equity:(139)(75)(53)(115)(111)(110)(50)
TOTAL LIABILITIES AND EQUITY:5087871391013

Income statement (P&L) ($ in thousands)

12/31/2018
Q4
12/31/2017
Q4
9/30/2017
Q3
6/30/2017
Q2
3/31/2017
Q1
12/31/2016
Q4
9/30/2016
Q3
Revenues(2)291217161112
Cost of revenue
(Cost of Goods and Services Sold)
(6) (9)(5)(2)  
Other undisclosed gross profit (29)   (17) 
Gross profit:(8)021214(6)12
Operating expenses(19)46(31)(14)(15)106(16)
Other operating income, net      3
Other undisclosed operating loss (30)   (30) 
Operating income (loss):(27)17(29)(2)(1)70(1)
Other undisclosed income from continuing operations before equity method investments, income taxes1    1 
Net income (loss):(26)17(29)(2)(1)71(1)
Other undisclosed net income (loss) attributable to parent(1)30   (133)(3)
Net income (loss) available to common stockholders, diluted:(27)47(29)(2)(1)(62)(5)

Comprehensive Income ($ in thousands)

12/31/2018
Q4
12/31/2017
Q4
9/30/2017
Q3
6/30/2017
Q2
3/31/2017
Q1
12/31/2016
Q4
9/30/2016
Q3
Net income (loss):(26)17(29)(2)(1)71(1)
Other comprehensive loss     (61)(4)
Other undisclosed comprehensive income 101     
Comprehensive income (loss):(26)117(29)(2)(1)10(5)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent20(13)(9)(2)(1)  
Comprehensive income (loss), net of tax, attributable to parent:(6)104(38)(4)(2)10(5)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: